SRTS

Sensus Healthcare, Inc.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Sensus Healthcare, Inc. (SRTS) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (C). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -22.1
EV / EBITDA -3.0
Rev Growth YoY -68.7%
Gross Margin 36.4%
Price Return 3M -19.8%
Price Return 12M -49.5%
Catalyst Signal 0.00
Market Cap $38.3M
TTM Revenue $17.5M
Price / Sales 2.2
ROE -34.8%

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) C+ (2.8) C+ (2.8) C (2.2) C+ (2.6) C+ (2.7)
2026-11-08 B- (3.0) C+ (2.7) C+ (2.8) C+ (2.7) C+ (2.6) C+ (2.8)
2026-11-01 B- (3.0) C+ (2.7) C+ (2.8) C (2.4) C+ (2.7) C+ (2.7)
2026-10-25 B- (3.0) C+ (2.6) C+ (2.8) C (2.3) C+ (2.6) C+ (2.7)
2026-10-18 B- (3.0) C+ (2.7) C+ (2.8) C- (2.1) C+ (2.6) C+ (2.6)
Page 1 of 8
…